diff --git a/domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md b/domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md
index 6061ae055..9c9d7c0b2 100644
--- a/domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md
+++ b/domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md
@@ -60,3 +60,10 @@ Lilly Employer Connect's $449/month net price for Zepbound 'doesn't appear to be
 **Source:** HR Brew/PR Newswire Q1 2026 DTE program launches
 
 Both Novo Nordisk (via 9amHealth No-Barriers Bundle and Waltz Health DTE program, launched January 1, 2026) and Eli Lilly now operate DTE channels. 9amHealth integrates access to FDA-approved obesity medications from BOTH manufacturers at fixed monthly costs, creating a multi-manufacturer DTE platform. However, expert consensus characterizes this as 'incremental governance shift, not structural PBM displacement' and 'manufacturers positioning themselves as more active participants in employer access strategy' rather than true intermediation disruption. Neither manufacturer has disclosed enrollment data or market penetration.
+
+
+## Supporting Evidence
+
+**Source:** Medical Economics, November 2025
+
+Cost Plus Drugs' partnership with Humana for 'end-to-end employer prescription solutions' represents another direct-to-employer channel that bypasses traditional PBM spread pricing through transparent cost-plus-15% pricing. However, the fact that Cost Plus chose to partner with Humana's CenterWell Pharmacy rather than build independent distribution infrastructure suggests that direct channels still require incumbent partnerships for scale, limiting the disintermediation potential.
diff --git a/entities/health/cost-plus-drug-company.md b/entities/health/cost-plus-drug-company.md
new file mode 100644
index 000000000..ee98e8f34
--- /dev/null
+++ b/entities/health/cost-plus-drug-company.md
@@ -0,0 +1,60 @@
+---
+type: entity
+entity_type: company
+name: Mark Cuban Cost Plus Drug Company
+founded: 2022
+headquarters: Dallas, TX
+founders: Mark Cuban, Alex Oshmyansky
+status: active
+website: costplusdrugs.com
+domain: health
+tags: [pharmacy, drug-pricing, PBM-alternative, generics, biosimilars]
+---
+
+# Mark Cuban Cost Plus Drug Company
+
+## Overview
+
+Cost Plus Drug Company is a direct-to-consumer pharmacy founded in 2022 by Mark Cuban and Alex Oshmyansky. The company operates on a transparent pricing model: acquisition cost + 15% markup + $3 pharmacy fee + $5 shipping, offering over 2,300 medications (primarily generics).
+
+## Business Model
+
+**Pricing Structure:**
+- Acquisition cost + 15% fixed fee
+- No insurance intermediation for direct-to-consumer sales
+- Transparent pricing published online
+
+**Product Portfolio:**
+- 2,300+ medications (mostly generics)
+- Expanding into biosimilar portfolio
+- Pursuing US manufacturing expansion with generic drug fee waivers
+
+**Distribution Strategy:**
+- Partnership with Humana CenterWell Pharmacy for employer prescription solutions (2025)
+- Combines Cost Plus pass-through pricing with CenterWell distribution infrastructure
+- Dependent on incumbent partnerships rather than independent distribution
+
+## Market Position
+
+**Competitive Context:**
+- Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) control ~80% of US prescription claims
+- Cost Plus operates as challenger model coexisting with incumbents
+- Growing market share but partnering with incumbents (Humana) rather than displacing PBMs
+
+**Political Role:**
+- Mark Cuban testified at congressional hearings on PBM practices
+- Supported FTC investigations into PBM business practices
+- Functions as political/narrative pressure vehicle even with small market share
+
+## Limitations
+
+- Primarily generic drugs — does not address branded/biologic drugs where margins are highest
+- No owned distribution infrastructure — dependent on partnerships
+- No clinical services layer — drug pricing tool, not care delivery model
+- Has not achieved meaningful market share in specialty drugs where margin extraction is concentrated
+
+## Timeline
+
+- **2022** — Company founded by Mark Cuban and Alex Oshmyansky
+- **2025-11** — Partnership announced with Humana CenterWell Pharmacy for employer prescription solutions
+- **2026** — Expanding biosimilar portfolio and pursuing US manufacturing expansion
\ No newline at end of file
diff --git a/inbox/queue/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md b/inbox/archive/health/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md
similarity index 98%
rename from inbox/queue/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md
rename to inbox/archive/health/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md
index 9775538af..565e695af 100644
--- a/inbox/queue/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md
+++ b/inbox/archive/health/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md
@@ -7,10 +7,13 @@ date: 2025-11-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-29
 priority: low
 tags: [pharmacy-benefits, PBM, Cost-Plus-Drugs, market-competition, drug-pricing, structural-reform]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content